Trava Health review

Trava's distinguishing feature is that you can actually follow the chain from checkout to vial. Six 503A compounding pharmacies are named on its own Terms and Telehealth Consent pages, clinical care runs through Beluga Health and Bask Health, and batch testing is stated as performed by Eagle Analytical, an FDA-registered lab. Its sermorelin is a single clean product at 3 mg for $157.91 a month with shipping included, and the homepage tile and product page agree. Its NAD⁺ does not: the tile reads "As Low As $127.86" while the product page reads "$158.93 / monthly — Save $127.86 with Our Quarterly Package". The tile is showing the discount as the price.

Trava Health is a Houston-based direct-to-consumer telehealth service co-founded by Charles Willis and Christopher Quintana, selling compounded medication across four categories: Weight Loss (compounded semaglutide and tirzepatide, each paired with B12), Anti-Aging & Wellness (NAD⁺ injection, NAD⁺ nasal spray, Lipo-B + B12, Lipo-C, vitamin B12, glutathione, metformin), Peptide Therapy (sermorelin) and Skincare (tretinoin). It discloses six 503A compounding pharmacy partners on its own legal pages — Postmeds/TruePill, EHT/Curexa, Apostrophe Pharmacy LLC, XeCare LLC, Wells American Inc dba Promed Pharmacy and Optimal Balance Pharmacy LLC dba OBP — and names Beluga Health and Bask Health as its clinical partners.

Quiz-led and asynchronous, with the consultation stated as included and no upfront payment required to begin. The disclosure posture is the reason to look at it. Naming one compounding pharmacy is unusual; naming six on your own Terms and Telehealth Consent pages, with legal entity names rather than trade names, means the specific facility filling your order is at least drawn from a knowable set. Stating that batches are independently tested by Eagle Analytical, an FDA-registered lab, is a second real check. Set against that is a trust profile that has not caught up. No LegitScript badge is surfaced anywhere. Its clinician roster link leads to a "page not found" error, so the named clinical partnerships are not matched by named clinicians. No founder or CEO is identified on the site itself. And it carries an F rating with the Better Business Bureau tied to unanswered complaints, on a file opened in 2025, without accreditation. Which pharmacy fills a given order can vary, so if the source matters to you, ask before the first shipment rather than after.

Product-page pricing is per molecule, monthly, and states what is included — shipping and handling at no additional cost, shipped via FedEx — with a quarterly package offered as the only discount structure. Sermorelin is $157.91 a month at 3 mg, and the homepage tile shows the identical figure, so you can take it at face value. NAD⁺ is where it breaks. The product page reads "$158.93 / monthly" for a 100 mg injection with a quarterly package saving $127.86; the homepage tile advertises the same product as "As Low As $127.86". Those cannot both be right, and the shape of the error is clear — the tile is displaying the quarterly saving in the price slot. Go by the product page's $158.93 a month for NAD⁺, and confirm it at checkout. The same tile pattern runs across the site, so check every headline against the product page before comparing anything: its GLP-1 tiles show $88.65 (semaglutide) and $178.98 (tirzepatide), and those are worth checking against the product page before you order. Higher-dose pricing on the GLP-1 side is gated behind the questionnaire rather than published.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Trava's six named 503A partners and its stated independent batch testing by Eagle Analytical are strong provenance disclosures, but compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are, and a compounded preparation of a molecule is not the trialed product. On evidence, its sermorelin, NAD⁺ and glutathione sit at different tiers. Sermorelin is a GHRH analog that stimulates your own pituitary rather than replacing growth hormone — a real, well-characterized mechanism whose long-term human outcome data stays thin beyond short-term IGF-1 movement, and Trava's 3 mg presentation is at least a specification you can compare. Injected and intranasal NAD⁺ have no controlled human outcome trials at all; the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears plasma quickly, and the forms with human trial data are the oral precursors NR and NMN, which raise a blood level rather than demonstrate an outcome. Injectable glutathione has essentially no controlled human outcome data behind the detoxification and skin claims attached to it. Individual results vary.